KKR-Backed Clinical Trials Co. Prices $660M Stock Offering
PRA Health Sciences Inc. on Tuesday priced an estimated $660 million secondary offering that enables Kohlberg Kravis Roberts & Co. to nearly halve its stake in the clinical trials company, marking...To view the full article, register now.
Already a subscriber? Click here to view full article